Overview
CENTOGENE provides advanced genetic and multiomic testing for rare, neurodegenerative, neurological, oncology, endocrinology, and other diseases, powered by the world's largest genetic testing portfolio covering 19,000 genes and the CENTOGENE Biodatabank. Their solutions include genome-wide CNV analysis via CentoArray, comprehensive NGS panels like CentoNeuro, and global sample logistics with CentoCard. The company aims to cure 100 rare diseases in the next decade, prioritizing neurological and metabolic disorders.
Frequently asked questions
- What diagnostic capabilities does CENTOGENE offer?
- CENTOGENE offers the world's largest genetic testing portfolio with 19,000 genes, including NGS panels for neurology (CentoNeuro), oncology, endocrinology, osteology, ENT, and genome-wide CNV analysis via CentoArray, powered by their Biodatabank and global network.
- What is CENTOGENE's focus in rare disease research?
- CENTOGENE has a mission to cure 100 rare diseases within the next 10 years, prioritizing rare neurological and metabolic disorders like Gaucher and Parkinson’s, with goals to expand their biobank to one million patients and develop 10 full disease models.
- What geographies and logistics does CENTOGENE support?
- CENTOGENE operates a global clinical network and proprietary CentoCard-based sample logistics system for rapid worldwide diagnostics, serving patients from neonatal cases to adults with complex disorders.